2L9 Stock Overview A precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Blueprint Medicines Corporation Competitors Price History & Performance
Summary of share price highs, lows and changes for Blueprint Medicines Historical stock prices Current Share Price US$107.40 52 Week High US$111.00 52 Week Low US$67.00 Beta 0.62 1 Month Change 27.64% 3 Month Change 17.43% 1 Year Change 52.34% 3 Year Change 54.98% 5 Year Change 90.09% Change since IPO 315.96%
Recent News & Updates
Blueprint Medicines Corporation Revises Revenue Guidance for the Full Year 2024 Nov 02
Third quarter 2024 earnings released: US$0.89 loss per share (vs US$2.20 loss in 3Q 2023) Nov 01
Forecast to breakeven in 2026 Oct 30
Blueprint Medicines Corporation to Report Q3, 2024 Results on Oct 30, 2024 Oct 16
No longer forecast to breakeven Aug 02
Blueprint Medicines Corporation Raises Revenue Guidance for the Full Year 2024 Aug 01 See more updates
Blueprint Medicines Corporation Revises Revenue Guidance for the Full Year 2024 Nov 02
Third quarter 2024 earnings released: US$0.89 loss per share (vs US$2.20 loss in 3Q 2023) Nov 01
Forecast to breakeven in 2026 Oct 30
Blueprint Medicines Corporation to Report Q3, 2024 Results on Oct 30, 2024 Oct 16
No longer forecast to breakeven Aug 02
Blueprint Medicines Corporation Raises Revenue Guidance for the Full Year 2024 Aug 01
Forecast to breakeven in 2026 Jul 23
Blueprint Medicines Corporation to Report Q2, 2024 Results on Aug 01, 2024 Jul 18
Chief Scientific Officer recently sold €387k worth of stock Jun 10
Blueprint Medicines Corporation to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting May 24
Forecast to breakeven in 2026 May 06 Blueprint Medicines Corporation Revises Revenue Guidance for the Full Year 2024 May 03
First quarter 2024 earnings released: EPS: US$1.45 (vs US$2.16 loss in 1Q 2023) May 03
Blueprint Medicines Corporation, Annual General Meeting, Jun 12, 2024 Apr 28
Blueprint Medicines Corporation to Report Q1, 2024 Results on May 02, 2024 Apr 20
President recently sold €1.0m worth of stock Mar 13
Blueprint Medicines Highlights AYVAKIT (Avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting Feb 24
New minor risk - Shareholder dilution Feb 17
Full year 2023 earnings released: US$8.37 loss per share (vs US$9.35 loss in FY 2022) Feb 16
Forecast to breakeven in 2026 Feb 16
Blueprint Medicines Corporation Provides Revenue Guidance for the Full Year 2024 Feb 15
Blueprint Medicines Corporation to Report Q4, 2023 Results on Feb 15, 2024 Feb 02
Blueprint Medicines' Ayvakyt (Avapritinib) Receives European Commission Approval as the First and Only Treatment for Indolent Systemic Mastocytosis Dec 13
Blueprint Medicines' Leadership in Driving Continued Innovation in Systemic Mastocytosis Highlighted At 2023 Ash Annual Meeting Dec 11
Blueprint Medicines' Ayvakyt (Avapritinib) Receives Positive Chmp Opinion as the First and Only Therapy for Indolent Systemic Mastocytosis Nov 12
New major risk - Share price stability Oct 28
Third quarter 2023 earnings released: US$2.20 loss per share (vs US$2.23 loss in 3Q 2022) Oct 27
Blueprint Medicines Corporation to Report Q3, 2023 Results on Oct 26, 2023 Oct 13
Second quarter 2023 earnings released: US$2.19 loss per share (vs US$2.68 loss in 2Q 2022) Aug 03
Chief Scientific Officer recently sold €112k worth of stock Jun 08
Blueprint Medicines Announces Clinical Data for Multiple Programs Across its Precision Therapy Portfolio at the 2023 American Society of Clinical Oncology Jun 04
Blueprint Medicines Corporation Announces NEJM Evidence Publishes Results from Registrational PIONEER Trial Demonstrating Significant Clinical Benefits of AYVAKIT (avapritinib) in Patients with Indolent Systemic Mastocytosis May 24
Blueprint Medicines Corporation Announces U.S. Food and Drug Administration Approves AYVAKIT(R) (avapritinib) as the First and Only Treatment for Indolent Systemic Mastocytosis May 23
Blueprint Medicines Corporation Provides Revenue Guidance for the Year 2023 May 05
First quarter 2023 earnings released: US$2.16 loss per share (vs US$1.79 loss in 1Q 2022) May 05
Insider recently sold €72k worth of stock Mar 10
Full year 2022 earnings released: US$9.35 loss per share (vs US$11.01 loss in FY 2021) Feb 18
Blueprint Medicines Corporation Provides Revenue Guidance for the Full Year of 2023 Feb 17
Blueprint Medicines Corporation Announces Partial Clinical Hold for Phase 1/2 Vela Trial of Blu-222 Feb 11
Blueprint Medicines Corporation to Report Q4, 2022 Results on Feb 16, 2023 Feb 10
Blueprint Medicines Corporation Announces FDA Acceptance of Supplemental New Drug Application for AYVAKIT(R) Jan 24
Blueprint Medicines Corporation Announces Board Changes Jan 07
Blueprint Medicines Corporation Reports Clinical Data Highlighting Leadership in Developing Targeted Treatment Options for Patients with Systemic Mastocytosis Dec 12
Blueprint Medicines Submits Supplemental New Drug Application to FDA for AYVAKIT® (Avapritinib) for the Treatment of Indolent Systemic Mastocytosis Nov 23
Third quarter 2022 earnings released: US$2.23 loss per share (vs US$2.00 loss in 3Q 2021) Nov 02
Blueprint Medicines Corporation Provides Revenue Guidance for 2022 Nov 02
President of Research & Development recently sold €235k worth of stock Oct 08
Blueprint Medicines Corporation Announces CANCER Publishes Study Demonstrating Substantial Disease Burden for Patients with Systemic Mastocytosis Aug 25
Blueprint Medicines Announces Positive Top-Line Results from Pioneer Trial of AYVAKIT® (Avapritinib) in Patients with Non-Advanced Systemic Mastocytosis Achieving Primary and All Key Secondary Endpoints Aug 18
Insider recently sold €309k worth of stock Aug 10
Second quarter 2022 earnings released: US$2.68 loss per share (vs US$1.86 loss in 2Q 2021) Aug 03
Blueprint Medicines Corporation Provides Revenue Guidance for 2022 Aug 03 Blueprint Medicines Corporation announced that it expects to receive $400 million in funding from Sixth Street Partners Jul 02
Blueprint Medicines Appoints Habib Dable to its Board of Directors Jun 24
Chief Scientific Officer recently sold €107k worth of stock Jun 09
Insufficient new directors May 31
Blueprint Medicines Corporation Provides Revenue Guidance for the Year 2022 May 05
Blueprint Medicines Corporation, Annual General Meeting, Jun 21, 2022 May 02
Blueprint Medicines Corporation Announces Blu-945 Proof-Of-Concept Data Supporting Initiation of Comprehensive Combination Development Strategy in Egfr-Mutant Non-Small Cell Lung Cancer Apr 09
Blueprint Medicines Corporation and Proteovant Therapeutics Announce Strategic Collaboration to Advance Novel Targeted Protein Degrader Therapies Mar 01
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Feb 17
Blueprint Medicines Corporation Provides Earnings Guidance for 2022 Feb 17
Blueprint Medicines Corporation to Report Q4, 2021 Results on Feb 16, 2022 Feb 10
Blueprint Medicines Corporation's AYVAKYT® (avapritinib) Receives Positive CHMP Opinion for the Treatment of Adults with Advanced Systemic Mastocytosis Jan 30
Blueprint Medicines Corporation (NasdaqGS:BPMC) completed the acquisition of Lengo Therapeutics, Inc. Dec 31
Blueprint Medicines Corporation Publishes Results from Two Registration Studies of Ayvakit® (Avapritinib) Showing Sustained Benefits in Patients with Advanced Systemic Mastocytosis Dec 09
Insufficient new directors Dec 06
Blueprint Medicines Corporation (NasdaqGS : BPMC) agreed to acquire Lengo Therapeutics, Inc. for $470 million. Nov 30
President of Research & Development recently sold €274k worth of stock Oct 08
Second quarter 2021 earnings released: US$1.86 loss per share (vs US$2.28 loss in 2Q 2020) Aug 02
High number of new directors Jul 31
FDA Approves Blueprint Medicines' AYVAKIT™ (avapritinib) for the Treatment of Adults with Advanced Systemic Mastocytosis Jun 17
Independent Chairman of the Board Daniel Lynch has left the company Jun 09
Blueprint Medicines Corporation Presents ARROW Trial Data for GAVRETO® May 21
First quarter 2021 earnings released: US$1.72 loss per share (vs US$2.11 loss in 1Q 2020) May 01
Investor sentiment improved over the past week Mar 16
CEO, President & Director recently sold €647k worth of stock Mar 06
New 90-day low: €74.52 Mar 05
Chief Scientific Officer has left the company Mar 03
Full year 2020 earnings released: EPS US$5.76 (vs US$7.27 loss in FY 2019) Feb 19
Revenue beats expectations Feb 19
Blueprint Medicines Corporation to Report Q4, 2020 Results on Feb 17, 2021 Feb 11
New 90-day low: €78.12 Jan 28 Blueprint Medicines Announces Management Changes
New 90-day high: €98.50 Dec 22
Blueprint Medicines Corporation Submits Supplemental New Drug Application to FDA for Ayvakit™ (Avapritinib) for the Treatment of Advanced Systemic Mastocytosis Dec 19
Blueprint Medicines Announces U.S. FDA Approval of GAVRETO for the Treatment of Patients with Advanced or Metastatic Ret-Mutant and Ret Fusion-Positive Thyroid Cancer Dec 11
Blueprint Medicines Announces FDA Approval of GAVRETO (pralsetinib) for the Treatment of Patients with Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid Cancer Dec 02
New 90-day high: €89.10 Nov 27
Third quarter 2020 earnings released: EPS US$11.49 Nov 02
Revenue beats expectations Nov 02
Third-quarter earnings released: Revenue beats expectations Oct 30
New 90-day high: €87.92 Oct 26
New 90-day high: €83.42 Oct 10
Blueprint Medicines Announces European Commission Approval of AYVAKYT (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA D842V Mutant Gastrointestinal Stromal Tumors Sep 26 Shareholder Returns 2L9 DE Biotechs DE Market 7D -0.09% -0.9% 0.3% 1Y 52.3% -6.0% 12.9%
See full shareholder returns
Return vs Market: 2L9 exceeded the German Market which returned 13.3% over the past year.
Price Volatility Is 2L9's price volatile compared to industry and market? 2L9 volatility 2L9 Average Weekly Movement 7.7% Biotechs Industry Average Movement 6.2% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.4% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 2L9's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 2L9's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations.
Show more Blueprint Medicines Corporation Fundamentals Summary How do Blueprint Medicines's earnings and revenue compare to its market cap? 2L9 fundamental statistics Market cap €6.82b Earnings (TTM ) -€123.35m Revenue (TTM ) €418.47m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 2L9 income statement (TTM ) Revenue US$434.42m Cost of Revenue US$12.93m Gross Profit US$421.48m Other Expenses US$549.53m Earnings -US$128.05m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -2.02 Gross Margin 97.02% Net Profit Margin -29.48% Debt/Equity Ratio 206.9%
How did 2L9 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/04 17:38 End of Day Share Price 2025/02/04 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources Blueprint Medicines Corporation is covered by 32 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Colleen Kusy Baird Ishan Majumdar Baptista Research Peter Lawson Barclays
Show 29 more analysts 
